Riverside

Texas to receive bamlanivimab, COVID-19 antibody treatment – Riverside, California

Riverside, California 2020-11-19 15:19:33 –

More than 300 hospitals across Texas are expected to receive experimental antibody treatment for COVID-19.

Lubbock, Texas — Governor of Texas, Greg Abbott, was in Lubbock on Thursday to provide updates on the distribution of Bamurani Bimab in the state.

According to the Texas Department of Health, more than 300 hospitals across Texas are expected to receive experimental antibody treatment for COVID-19. Hospitals in the trauma service area of ​​Houston and Galveston / Beaumont receive more than 700 doses.

The US Food and Drug Administration has urgently approved the bamlani vimab created by Eli Lilly and Company.

According to Lily, treatment of mild to moderate COVID-19 is approved for adults and pediatric patients aged 12 years and older who are at high risk of progressing to severe COVID-19 and have a positive COVID-19 test. ..

Bamuranibimab should be given as soon as possible within 10 days of the onset of symptoms after a positive COVID-19 test. Healthcare professionals give it by intravenous infusion.

Relation: More than 300 Texas hospitals receiving “Bamurani Bimab”, an experimental antibody treatment for COVID-19

Relation: US permits first emergency use of experimental COVID-19 antibody drug

Clinical trials have shown that it can prevent patients from going to the hospital. This indication may help healthcare professionals who have been fighting the virus for eight months.

Bamurani Bimab Absent Allowed for use on patients:

  • Those who are hospitalized for COVID-19, or
  • Those who need oxygen therapy for COVID-19, or
  • Those who are receiving chronic oxygen therapy due to an underlying non-COVID-19-related comorbidity and who require increased baseline oxygen flow with COVID-19.

According to DSHS, Texas receives the second largest shipment of medicines after Illinois.

Texas to receive bamlanivimab, COVID-19 antibody treatment Source link Texas to receive bamlanivimab, COVID-19 antibody treatment

Back to top button